Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc  

(Public, TSE:MSL)   Watch this stock  
Find more results for tse:msl
+0.04 (2.55%)
Dec 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.58 - 1.69
52 week 1.08 - 2.68
Open 1.62
Vol / Avg. 559,188.00/389,470.00
Mkt cap 130.79M
P/E     -
Div/yield     -
EPS -0.06
Shares 81.23M
Beta 0.29
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -2.39% -6.09%
Operating margin 9.34% 19.40%
EBITD margin - 64.72%
Return on average assets -0.57% -1.93%
Return on average equity -0.84% -4.37%
Employees 6 -
CDP Score - -


100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
+1-416-5933725 (Phone)

Website links


Merus Labs International Inc. (Merus), formerly Envoy Capital Group Inc., is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It has products in the area of urology/women's health, anti-infective, and wound care. Its products include Factive, Emselex/Enable, Vancocin and Collacare and Collexa. On January 6, 2012, the Company acquired 51% of Orbis Pharma Inc. On March 7, 2012, the Company completed the acquisition of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc. In August 2013, the Company announced that the divestiture of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets to Okana Ventures Inc.

Officers and directors

David D. Guebert CPA Independent Chairman of the Board
Barry Fishman Chief Executive Officer, Director
Ahmad Doroudian Executive Vice Chairman of the Board
Age: 50
Andrew Patient Chief Financial Officer
Ulrich Schoeberl Managing Director, European Operations
Theresa Firestone Director
Robert S. Pollock Independent Director
Timothy G. Sorensen Independent Director
Michael S. Cloutier Non-Executive Independent Director